USPTO Examiner TRUONG QUANGLONG N - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19013003PHARMACEUTICAL SOLUTION OF AMLODIPINEJanuary 2025June 2025Allow510NoNo
18893805TREATMENT OF DIABETIC RETINOPATHY WITH OPHTHALMIC COMPOSITIONSSeptember 2024April 2025Allow610NoNo
18893796STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONSSeptember 2024May 2025Allow810NoNo
18893790TREATMENT OF OCULAR INFLAMMATION FOLLOWING OCULAR SURGERYSeptember 2024May 2025Allow710YesNo
18893806PH STABILIZED OPHTHALMIC DEXAMETHASONE COMPOSITIONSSeptember 2024May 2025Allow810YesNo
18893810PH STABILIZED OPHTHALMIC COMPOSITIONSSeptember 2024May 2025Allow810NoNo
18816200PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOFAugust 2024January 2025Allow510NoNo
18797696Mycophenolate Oral SuspensionAugust 2024November 2024Allow310YesNo
18797717Mycophenolate Oral SuspensionAugust 2024December 2024Allow410NoNo
18664253SURGICAL REPAIR GRAFTMay 2024May 2025Allow1210YesNo
18653190PHARMACEUTICAL SOLUTION OF AMLODIPINEMay 2024October 2024Allow510NoNo
18703772SKIN BARRIER PROTECTIVE DELIVERY SYSTEMSApril 2024September 2024Allow410NoNo
18703841SKIN BARRIER PROTECTIVE DELIVERY SYSTEMSApril 2024August 2024Allow410YesNo
18703824APIXABAN SUSPENSION AND PREPARATION METHODApril 2024September 2024Allow510NoNo
18629986DISSOLVING MICRONEEDLE CONTAINING CANNABIDIOL SUSPENSION AND PREPARATION METHOD THEREOFApril 2024August 2024Allow410YesNo
18628237TOPICAL COMPOSITIONS COMPRISING EMULSIFIED POVIDONE IODINE SOLUTIONS AND METHODS OF PREPARATIONApril 2024June 2025Allow1410YesNo
18605258PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORSMarch 2024June 2025Allow1510NoNo
18442802Mycophenolate Oral SuspensionFebruary 2024July 2024Allow510YesNo
18442765Mycophenolate Oral SuspensionFebruary 2024August 2024Allow610YesNo
18434065SUSTAINED RELEASE MELATONIN COMPOSITIONSFebruary 2024July 2024Allow610YesNo
18545896COMPOSITION FOR TREATING NIGHT BLINDNESSDecember 2023August 2024Allow720NoNo
18534301SELF-EMULSIFYING CANNABIDIOL FORMULATIONSDecember 2023January 2025Allow1410YesNo
18518202PHARMACEUTICAL COMPOSTION CONTAINING ACETOMINOPHEN AND IBUPROFENNovember 2023September 2024Allow910YesNo
18445610Method of Arthropod EgressNovember 2023November 2024Allow1230NoNo
18498661Devices and Methods for Delivering Methane Inhibiting Compounds to AnimalsOctober 2023June 2024Allow710YesNo
18384000TREATMENT OF DIABETIC RETINOPATHYOctober 2023May 2024Allow620YesNo
18383991STABILIZED DEXAMETHASONE COMPOSITIONSOctober 2023May 2024Allow610NoNo
18383993TREATMENT OF OCULAR INFLAMMATIONOctober 2023May 2024Allow610NoNo
18380472FLOWABLE ACELLULAR TISSUE MATRIX PRODUCTS AND METHODS OF PRODUCTIONOctober 2023November 2024Abandon1310NoNo
18378069TOPICAL COMPOSITIONS COMPRISING EMULSIFIED POVIDONE IODINE SOLUTIONS AND METHODS OF PREPARATIONOctober 2023February 2024Allow510NoNo
18553911LYOPHILIZED COMPOSITION OF COPANLISIB SALTOctober 2023August 2024Abandon1010NoNo
18372165CONTROLLED DRUG RELEASE FROM ELECTROSPUN FIBERSSeptember 2023September 2024Allow1210NoNo
18472426DRUG DELIVERY SYSTEMSSeptember 2023October 2024Abandon1310NoNo
18371163FILM-FORMING COMPOSITION CONTAINING SURFACTANT OR SURFACTANT AND SALT AS WHITENING AGENTSeptember 2023March 2025Allow1810YesNo
18369241ABUSE AND MISUSE DETERRENT TRANSDERMAL SYSTEMSSeptember 2023January 2025Allow1610NoNo
18369754Oral Dosage Forms Comprising a Hops ExtractSeptember 2023December 2024Allow1510NoNo
18448990COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC PAIN AND DEPRESSIONAugust 2023February 2024Allow610YesNo
18362179PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGEJuly 2023February 2024Allow620NoNo
18359685N-ACETYLCYSTEINE COMPOSITIONS AND METHODSJuly 2023June 2024Allow1010NoNo
18352356KOMBUCHA NATURAL HEALTH PRODUCTSJuly 2023August 2024Allow1310YesNo
18214770PHARMACEUTICAL COMPOSITIONS COMPRISING ISOTRETINOIN AND PROCESSES FOR PREPARATION AND USES THEREOFJune 2023February 2024Allow810YesNo
18339267PHARMACEUTICAL SOLUTION OF AMLODIPINEJune 2023February 2024Allow810NoNo
18323101PHARMACEUTICAL COMPOSITION COMPRISING ADRENALINEMay 2023February 2024Allow920NoNo
18200828MELT PROCESSED VIRAL NANOPARTICLE CONSTRUCTSMay 2023July 2024Allow1410YesNo
18316850COMPOSITION COMPRISING HIGHLY-CONCENTRATED ALPHA1 PROTEINASE INHIBITOR AND METHOD FOR OBTAINING THEREOFMay 2023July 2024Allow1410NoNo
18141357EXTRACT OF AGATHIS ROBUSTA AS ANTIFUNGAL AGENTApril 2023December 2023Allow720NoNo
18301072Compositions Comprising One or More (Bio)-Alkanediols with AntioxidantsApril 2023December 2023Allow810YesNo
18190372Method for Preparing High-load Oral Paclitaxel Capsule for Slow Release in ColonMarch 2023August 2023Allow410NoNo
18126251METHODS OF TREATMENT USING CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONSMarch 2023February 2024Allow1010YesNo
18126138WHIPPED FORMULATIONSMarch 2023July 2024Allow1610YesNo
18124462BLEND COMPOSITIONS FOR ORAL ADMINISTRATION AS A RAPIDLY DISSOLVING POWDER AND/OR SUSPENSIONMarch 2023February 2024Allow1010NoNo
18124291WHIPPED FORMULATIONSMarch 2023April 2024Abandon1310YesNo
18123292MICRONEEDLE ARRAY WITH ACTIVE INGREDIENTMarch 2023July 2024Abandon1610NoNo
18120054Solid Forms and Methods of Preparing the SameMarch 2023August 2024Allow1810NoNo
18114304IMPLANTABLE NANOCHANNEL DELIVERY DEVICESFebruary 2023July 2024Allow1610YesNo
18157653SURGICAL REPAIR GRAFTJanuary 2023February 2024Allow1310YesNo
18154524STABLE PILOCARPINE FORMULATIONS WITH MODIFIED BUFFER CHARACTERISTICS AND RELATED METHODSJanuary 2023August 2023Allow710NoNo
18150590CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDE AND METHODS OF ADMINISTERING THE SAMEJanuary 2023March 2024Allow1510YesNo
18088375LIQUID PHARMACEUTICAL FORMULATIONS OF TAFAMIDISDecember 2022March 2024Allow1530YesNo
18087128POWDERED COLLAGEN WOUND CARE COMPOSITIONSDecember 2022August 2024Allow2020YesNo
18087608PHARMACEUTICAL COMPOSTION CONTAINING ACETOMINOPHEN AND IBUPROFENDecember 2022October 2023Allow910NoNo
18083977NICOTINE POUCHDecember 2022July 2023Allow710NoNo
18066196COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL FUNCTIONDecember 2022June 2024Allow1820YesNo
18009298Compositions Comprising One or More (Bio)-Alkanediols with AntioxidantsDecember 2022September 2024Allow2210YesNo
18058463Extract containing oleandrin and method of production thereofNovember 2022March 2024Allow1631NoNo
18055388KAOLINITE COMPOSITE DIAGNOSTIC AND THERAPEUTIC AGENT AND PREPARATION METHOD AND USE THEREOFNovember 2022September 2023Allow1010NoNo
17961690COMPOSITIONS FOR PREVENTION OF SIDE EFFECTS RELATED TO ALCOHOL CONSUMPTIONOctober 2022April 2024Abandon1811NoNo
17960817THERAPEUTIC PREPARATION OF ACTIVATED ST. JOHN'S WORTOctober 2022December 2023Allow1511YesNo
17943356MAGNETIC DRESSING AND PREPARATION METHOD AND USE THEREOFSeptember 2022December 2023Allow1520YesNo
17817731CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDEAugust 2022October 2022Allow200YesNo
17879041CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDEAugust 2022October 2022Allow200YesNo
17871058CALCIUM GLUCONATE FORMULATION WITHOUT CALCIUM SACCHARATEJuly 2022January 2023Allow610NoNo
17869482Methods of Treating Skin DiseasesJuly 2022December 2023Abandon1710NoNo
17811972DEEP PENETRATING TOPICAL CANNABINOID COMPOSITIONS AND METHODS FOR TREATING MUSCULOSKELETAL INFLAMMATION AND PAINJuly 2022April 2024Allow2110YesNo
17858405EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAMJuly 2022October 2023Abandon1510NoNo
17857587N-ACETYLCYSTEINE COMPOSITIONS AND METHODSJuly 2022April 2023Allow1010YesNo
17789098COMPOSITION FOR REMINERALIZING TOOTH ENAMELJune 2022July 2025Allow3610YesNo
17848290SALINE-BASED COMPOSITION FOR PIERCING AFTERCAREJune 2022April 2024Abandon2210NoNo
17842339SODIUM HYPOCHLORITE AND CHLORHEXIDINE BASED NANOEMULSIONS AND A METHOD OF PREPARATION THEREOFJune 2022August 2023Allow1421YesNo
17840829PHARMACEUTICAL SOLUTION OF AMLODIPINEJune 2022March 2023Allow921NoNo
17805967Fast Dispersing Suspending Composition, Method of Preparation And Application ThereofJune 2022February 2023Allow810YesNo
17834006NICOTINE POUCHJune 2022September 2022Allow310YesNo
17828129KOMBUCHA NATURAL HEALTH PRODUCTSMay 2022April 2023Allow1111YesNo
17727442HAIR LOTIONApril 2022December 2023Abandon2010NoNo
17724045PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORSApril 2022December 2023Allow2010NoNo
17708960COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUSMarch 2022September 2023Allow1710NoNo
17707192CROSSLINKABLE COATING COMPOSITIONS FORMULATED WITH DORMANT CARBAMATE INITIATORMarch 2022July 2023Allow1610NoNo
17687754ICARIIN NANO-PHARMACEUTICAL FORMULATIONMarch 2022August 2022Allow611NoNo
17688676METHOD AND DEVICE FOR IN VIVO BRONCHUS REGENERATIONMarch 2022June 2024Allow2720YesNo
17640620FOOD COMPOSITIONS FOR LACTATING WOMENMarch 2022March 2025Abandon3710NoNo
17675043CONCENTRATED LIQUID PHARMACEUTICAL FORMULATIONS OF FUROSEMIDEFebruary 2022July 2022Allow510YesNo
17675605MELT PROCESSED VIRAL NANOPARTICLE CONSTRUCTSFebruary 2022June 2025Allow4010NoNo
17673672Systems and Methods for Generating and Applying Biomimicry Tear FilmsFebruary 2022June 2023Allow1610YesNo
17671447COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIALFebruary 2022September 2023Abandon1910NoNo
17666727SYSTEM FOR DISPENSING A COSMETIC PRODUCTFebruary 2022January 2024Allow2320NoNo
17666846SYSTEM FOR DISPENSING A COSMETIC PRODUCTFebruary 2022August 2024Allow3130YesNo
17666802SYSTEM FOR DISPENSING A COSMETIC PRODUCTFebruary 2022February 2024Allow2420NoNo
17666760SYSTEM FOR DISPENSING A COSMETIC PRODUCTFebruary 2022January 2024Allow2420NoNo
17666714SYSTEM FOR DISPENSING A COSMETIC PRODUCTFebruary 2022January 2024Allow2320NoNo
17666783SYSTEM FOR DISPENSING A COSMETIC PRODUCTFebruary 2022February 2024Allow2420NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TRUONG, QUANGLONG N.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
2
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.1%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
21
Allowed After Appeal Filing
7
(33.3%)
Not Allowed After Appeal Filing
14
(66.7%)
Filing Benefit Percentile
47.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner TRUONG, QUANGLONG N - Prosecution Strategy Guide

Executive Summary

Examiner TRUONG, QUANGLONG N works in Art Unit 1615 and has examined 581 patent applications in our dataset. With an allowance rate of 77.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.

Allowance Patterns

Examiner TRUONG, QUANGLONG N's allowance rate of 77.5% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by TRUONG, QUANGLONG N receive 1.80 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by TRUONG, QUANGLONG N is 23 months. This places the examiner in the 74% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +22.4% benefit to allowance rate for applications examined by TRUONG, QUANGLONG N. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.2% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 31.2% of cases where such amendments are filed. This entry rate is in the 37% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.7% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 50.4% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.